Furthermore, increased CGB5 expression was significantly associated with DSS and PFI in GC patients, particularly in relation to clinical characteristics such as age, histological grading, pathological staging, and disease progression (Supplementary Figure S13). Here, CGB5 is linked to gastric cancer.